Doximity stock has plummeted 56% in 2026 amid concerns that AI could disrupt its medical platform services. However, the author argues these fears are overblown, citing the company's dominant 85%+ physician network, strong customer base (top 20 pharma companies and hospital systems), and regulatory barriers that protect it from easy disruption. Trading at 15x free cash flow, the author views it as a buying opportunity as pharma advertising spending should eventually rebound.

The Dow Jones climbed back above 50,000 driven by Cisco's strong earnings beat and guidance raise, while Nvidia gained on news of Chinese H200 chip approvals. However, the rally appears fragile as inflation data runs hot with import prices spiking 1.9% and energy costs surging, offsetting positive consumer resilience metrics. The Trump-Xi summit in Beijing provided mild sentiment support but delivered limited concrete deliverables.

Doximity stock fell 24% after reporting mixed Q4 2026 earnings with only 5% sales growth and disappointing 2027 guidance of 3-5% revenue growth. The company is increasing AI spending amid a soft healthcare advertising market, pressuring profitability. Despite industry headwinds, Doximity maintains its market leadership with 85% of U.S. physicians on its platform and trades at a cheap 12x forward earnings valuation.

U.S. stock futures rose on Thursday as President Trump addresses trade issues with China. Cisco Systems surged 18.8% on better-than-expected Q3 results and raised FY26 guidance. Doximity plunged 21.46% on mixed Q4 results and weak guidance. Grocery Outlet gained 16.41% after beating EPS estimates by 150%. The Fed is expected to hold rates steady in June with 98.6% probability. Nvidia's H200 chip sales to Chinese firms were cleared by the U.S., though Beijing halted deliveries.

Tech stocks surged on Wednesday despite a hotter-than-expected April PPI reading (6% YoY vs 4.8% expected), which rekindled inflation concerns. The Nasdaq 100 gained 0.7% led by semiconductor strength, while rate-sensitive sectors like utilities and financials declined. Nvidia hit record highs above $226 ahead of earnings, Ford surged 11.9% on strong Q1 results, and software stocks like Dynatrace and Doximity fell sharply on disappointing earnings.

Hot inflation data (April PPI up 1.4% vs 0.5% consensus) has forced markets to reprice lower rate-cut expectations, pressuring equities and extending Treasury yields to 4.475%. While semiconductor stocks rallied on Trump's Beijing summit and memory pricing strength, the broader market faces stretched valuations with asymmetric earnings reaction patterns favoring misses over beats. Kevin Warsh is set to become Fed chair amid the worst macro moment for establishing credibility.

Doximity (DOCS), a social network and software platform for doctors, has fallen 66% over the past year amid software stock selloffs driven by AI disruption fears. Despite the stock decline, the underlying business remains strong with 89.75% gross margins, 38.5% EBIT margins, and a dominant position serving 85% of U.S. physicians. Trading at a P/E of 21, the stock presents a buying opportunity for investors as the company expands into new software tools like DoxGPT.

Halper Sadeh LLC is investigating whether officers and directors of Doximity Inc. breached their fiduciary duties to shareholders. The firm is seeking long-term shareholders to participate in potential litigation for corporate governance reforms and financial recovery.

Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Driven Brands Holdings Inc. and Doximity Inc. breached their fiduciary duties to shareholders. The firm is encouraging long-term shareholders to contact them regarding potential corporate governance reforms and financial recovery options.

William Blair Investment Management sold 372,184 shares of Doximity (worth ~$21 million) in Q4 2025, reducing its position by 15%. Despite the sale, the author remains bullish on Doximity, citing its reasonable 17x free cash flow valuation, strong physician adoption (85% of U.S. doctors), and upcoming AI monetization opportunities in 2026. The stock has declined 66% year-over-year, partly due to temporary pharma spending delays that are now subsiding.

Doximity reported Q1 FY2026 results with revenue of $145.9 million, missing analyst expectations but beating earnings per share estimates. The company raised full-year guidance and showed strong performance in AI tool adoption and workflow solutions.

Two healthcare stocks, Hims & Hers Health and Doximity, have seen significant stock price growth over the past year, with potential for continued expansion in digital health and professional networking platforms.